PDF(Pubmed)
Abstract：
About half of the world\'s population is at risk of dengue infection. Epidemics of dengue fever have caused an increased risk of morbidity and mortality in recent years, which led to the exploration of vaccines as a preventive measure. This systematic review and meta-analysis aimed to evaluate the efficacy, immune response, and safety of dengue vaccines in children by analyzing clinical trials. The review followed standard procedures for data extraction using PRISMA guidelines and searching multiple databases, including PubMed, CINAHL, Medline, Health Source, Science Direct, and Academic Search Premiere. Eligible studies involved children (0-17 years old). Quality assessment was analyzed using the Cochrane Collaboration criteria, while data synthesis was conducted using thematic analysis and meta-analysis. Among the 38 selected studies, dengue vaccines showed varying efficacy against all four serotypes. The CYD-TDV (Dengvaxia®) and Tekade (TAK-003) vaccines showed strong protection against severe dengue, but their long-term efficacy varied. Vaccines triggered satisfactory immune responses, notably in those previously exposed to dengue. Safety profiles were mostly favorable, noting mild adverse events post-vaccination. Meta-analysis supported vaccine efficacy and immune response, but safety concerns warrant further exploration. In conclusion, dengue vaccines showed promising efficacy and immune response, particularly against severe manifestations.
摘要：
世界上大约一半的人口有感染登革热的危险。近年来,登革热的流行增加了发病和死亡的风险,这导致了疫苗作为预防措施的探索。这项系统评价和荟萃分析旨在评估疗效，免疫反应，通过分析临床试验，以及儿童登革热疫苗的安全性。审查遵循使用PRISMA指南和搜索多个数据库的数据提取标准程序，包括PubMed,CINAHL,Medline,健康来源,科学直接，和学术搜索首演。符合条件的研究涉及儿童（0-17岁）。质量评估使用Cochrane协作标准进行分析，而数据综合采用主题分析和荟萃分析。在选定的38项研究中，登革热疫苗对所有四种血清型均表现出不同的功效.CYD-TDV（Dengvaxia®）和Tekade（TAK-003）疫苗对严重登革热具有很强的保护作用，但它们的长期疗效各不相同。疫苗引发了令人满意的免疫反应，尤其是那些以前接触过登革热的人。安全状况大多是有利的，注意到疫苗接种后出现轻度不良事件.Meta分析支持疫苗疗效和免疫反应，但安全问题值得进一步探索。总之,登革热疫苗显示出有希望的功效和免疫反应，特别是针对严重的表现。
